试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-08
YQ23 Study in Patients With Critical Limb Ischaemia
编号:NCT04792008登记状态:提前终止企业 / 申办者:New Beta Innovation Limited
药物 / 成分:YQ23、Matching placebo
登记的停止原因(原文):Due to business decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-08
A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma
编号:NCT05193604登记状态:提前终止企业 / 申办者:Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
药物 / 成分:TQB2858 injection、Anlotinib Hydrochloride Capsule、Gemcitabine hydrochloride for injection、Paclitaxel for injection (albumin bound)
登记的停止原因(原文):Terminated due to the adjustment of sponsor's development strategies and pipeline.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-08
Evaluate RCN3028 in Treatment of Drug-Induced VMS in Breast Cancer
编号:NCT06161792登记状态:提前终止企业 / 申办者:Yung Shin Pharm. Ind. Co., Ltd.
药物 / 成分:0.8 mg RCN3028、Placebo
登记的停止原因(原文):Difficulty in recruiting breast cancer patients, leading to a slow rate of case enrollment.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-06
Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
编号:NCT02608268登记状态:提前终止企业 / 申办者:Novartis Pharmaceuticals
药物 / 成分:MBG453、PDR001、Decitabine
登记的停止原因(原文):Business reasons
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-06
Impulsivity and Alcohol Response
编号:NCT03736343登记状态:提前终止企业 / 申办者:University of Florida
药物 / 成分:Alcohol
登记的停止原因(原文):The COVID-19 outbreak began, precluding further participant recruitment for this protocol, which could only be conducted in-person. A decision was made that ample data was available to end data collection earlier than anticipated.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-06
Fecal Microbiota Transplantation After Autologous HSCT in Patients With Multiple Sclerosis
编号:NCT04203017登记状态:提前终止企业 / 申办者:St. Petersburg State Pavlov Medical University
药物 / 成分:allogeneic fecal microbiota
登记的停止原因(原文):the bio-samples are corrupted for technical reasons
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-06
A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy
编号:NCT04905212登记状态:提前终止企业 / 申办者:RemeGen Co., Ltd.
药物 / 成分:Telitacicept 160mg、Telitacicept 240mg、Placebo
登记的停止原因(原文):Decision that continuing with the study would not generate useful data
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-06
ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma
编号:NCT05116683登记状态:提前终止企业 / 申办者:Benjamin Izar
药物 / 成分:ATX-101
登记的停止原因(原文):Study terminated by PI
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-05
Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)
编号:NCT00758342登记状态:提前终止企业 / 申办者:Alcon Research
药物 / 成分:Travoprost 0.004% + Brinzolamide 1.0%、Travoprost 0.004% + Tears Natural
登记的停止原因(原文):difficulty of enrolling patients
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-12-05
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma
编号:NCT01856023登记状态:提前终止企业 / 申办者:Clinigen, Inc.
药物 / 成分:High Dose Interleukin-2、Ipilimumab
登记的停止原因(原文):slow accrual \& early closure
查看官方原始记录 ↗